Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report-Reference-Cited by-同舟云学术

Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report

Published:2020-07-21 Issue:10 Volume:31 Page:1008-1010
ISSN:0956-4624
Container-title:International Journal of STD & AIDS
language:en
Short-container-title:Int J STD AIDS

Author:

Riva Agostino¹,Cattaneo Dario²³^ORCID,Filice Carlo⁴,Gervasoni Cristina¹²^ORCID

Affiliation:

1. Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

2. Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

3. Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

4. Infectious Diseases Department, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy

Abstract

We report here the case of a 32-year-old male with recent diagnosis of HIV that, 45 days after starting a single tablet regimen co-formulated with bictegravir, emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), experienced severe epigastric pain radiating to the back, nausea, episodes of non-bloody non-bilious vomiting and anorexia. Laboratory examination showed a rise in lipase with no alterations in serum transaminases. Abdominal ultrasound revealed a non-homogeneous structure of the pancreatic parenchyma. A diagnosis of mild drug-related acute pancreatitis was made and BIC/FTC/TAF was immediately stopped. The association between the episode of acute pancreatitis and BIC/FTC/TAF was scored as probable according to the Naranjo causality scale.

Publisher

SAGE Publications

Subject

Infectious Diseases,Pharmacology (medical),Public Health, Environmental and Occupational Health,Dermatology

Link

http://journals.sagepub.com/doi/pdf/10.1177/0956462420934981

Reference10 articles.

1. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single‐tablet regimen in the expanding spectrum of fixed‐dose combination therapy for HIV

2. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

3. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

4. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

5. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of the pharmacist caring for people at risk of or living with HIV in Canada;Canadian Pharmacists Journal / Revue des Pharmaciens du Canada;2024-08-02

2. Pharmacokinetic interactions of modern antiretroviral therapy;AIDS;2021-12-15

3. Antiviral drugs;Side Effects of Drugs Annual;2021

4. Bictegravir/emtricitabine/tenofovir-alafenamide;Reactions Weekly;2020-10